IFG Advisory LLC Takes $361,000 Position in Moderna, Inc. $MRNA

IFG Advisory LLC bought a new stake in Moderna, Inc. (NASDAQ:MRNA) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,256 shares of the company’s stock, valued at approximately $361,000.

Other institutional investors also recently modified their holdings of the company. MUFG Securities EMEA plc bought a new stake in shares of Moderna in the second quarter valued at about $28,000. Flagship Harbor Advisors LLC bought a new stake in Moderna during the fourth quarter worth about $31,000. Ameriflex Group Inc. lifted its position in Moderna by 3,775.0% during the third quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock worth $32,000 after purchasing an additional 1,208 shares during the period. Cromwell Holdings LLC lifted its position in Moderna by 39.7% during the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after purchasing an additional 341 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its position in Moderna by 148.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after purchasing an additional 801 shares during the period. Institutional investors own 75.33% of the company’s stock.

Insider Activity

In other news, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $48.40, for a total value of $2,581,462.40. Following the completion of the transaction, the president owned 1,477,997 shares of the company’s stock, valued at $71,535,054.80. This represents a 3.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Abbas Hussain sold 5,682 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $46.63, for a total value of $264,951.66. Following the completion of the transaction, the director directly owned 12,066 shares of the company’s stock, valued at $562,637.58. This represents a 32.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 68,281 shares of company stock valued at $3,280,293 over the last quarter. 10.80% of the stock is owned by company insiders.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $47.19 on Monday. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. The company has a market cap of $18.72 billion, a price-to-earnings ratio of -5.79 and a beta of 1.05. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $59.55. The stock has a 50-day moving average price of $50.24 and a two-hundred day moving average price of $42.52.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing the consensus estimate of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The business had revenue of $389.00 million for the quarter, compared to analyst estimates of $236.37 million. During the same period in the previous year, the firm posted ($2.52) EPS. The firm’s revenue was up 260.2% compared to the same quarter last year. As a group, analysts forecast that Moderna, Inc. will post -6.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on MRNA shares. Royal Bank Of Canada upped their price objective on shares of Moderna from $35.00 to $38.00 and gave the stock a “sector perform” rating in a research report on Monday, May 4th. Jefferies Financial Group set a $37.00 price objective on shares of Moderna and gave the stock a “hold” rating in a research report on Tuesday, March 3rd. The Goldman Sachs Group upped their price objective on shares of Moderna from $43.00 to $49.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Evercore set a $35.00 price objective on shares of Moderna in a research report on Tuesday, February 17th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Moderna in a research report on Monday, February 16th. Two investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average price target of $35.73.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.